Oral Bisphosphonates and the Risk of Barrett's Esophagus: Case–Control Analysis of US Veterans

Oral Bisphosphonates and Risk of Esophageal Cancer: A Dose-Intensity Analysis in a Nationwide Population

(2012) Y.-F. Ho et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Novel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents

(2012) M. Thurnher et al.   CLINICAL CANCER RESEARCH

Waist-to-Hip Ratio, but Not Body Mass Index, Is Associated With an Increased Risk of Barrett's Esophagus in White Men

(2012) Jennifer R. Kramer et al.   Clinical Gastroenterology and Hepatology

The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett’s oesophagus

(2011) A. P. Thrift et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Molecular Mechanisms of Barrett’s Esophagus

(2011) Hao Chen et al.   DIGESTIVE DISEASES AND SCIENCES

Esophageal and gastric cancer incidence and mortality in alendronate users

(2011) Bo Abrahamsen et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Biochemical and molecular mechanisms of action of bisphosphonates

(2010) Michael J. Rogers et al.   BONE

Oral Bisphosphonate Prescriptions and the Risk of Esophageal Adenocarcinoma in Patients with Barrett’s Esophagus

(2010) Dang M. Nguyen et al.   DIGESTIVE DISEASES AND SCIENCES

Exposure to Oral Bisphosphonates and Risk of Esophageal Cancer

(2010) Chris R. Cardwell et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

How does inflammation cause Barrett's metaplasia?

(2009) Benjamin J Colleypriest et al.   CURRENT OPINION IN PHARMACOLOGY

Reports of Esophageal Cancer with Oral Bisphosphonate Use

(2009) Diane K. Wysowski   NEW ENGLAND JOURNAL OF MEDICINE

American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease

(2008) Peter J. Kahrilas et al.   GASTROENTEROLOGY